Skip to main content

We want to improve the way people age

by enhancing life quality through first-in-class therapies that restore local blood circulation

Many age-related diseases share impaired local blood flow as a fundamental underlying mechanism. This reduction in circulation leads to tissue degeneration, impaired repair processes, and the progression of chronic conditions with aging. Topadur’s dual mechanism of action approach restores targeted blood flow, reawakening the body’s natural regenerative capabilities.

OUR SCIENCE
Discover how our DualTOP™ platform stimulates microcirculation to activate regeneration
OUR PIPELINE
Addressing high unmet-needs with first-in-class therapies, from preclinical to clinical Phase 2 development
PARTNERING AND INVESTORS
Find out more about our corporate strategy, milestones, and strategic collaborations driving scientific and commercial progress
NEWS & EVENTS | STAY UP TO DATE
Topadur secures FDA Orphan Drug Designation for TOP-N53
Topadur Pharma AG today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational therapy…
9. September 2025

»Being recognized by esteemed institutions and supported by grants is a true testament to our team’s dedication and the real-world relevance of our work. These acknowledgments inspire us to continue pushing the frontiers of innovation.«

Reto Naef, Founder & CEO